Toggle light / dark theme

The emergence of the novel coronavirus and its associated disease, COVID-19, has led to a global pandemic and a call for individuals, in the name of overall public health and an attempt to prevent national medical systems from being overwhelmed with too many patients at once, to self-isolate, self-quarantine, and practice social distancing. Many of us are confronted, for perhaps the only time in our lives, with an uncertain span of time in solitude.

Although this is the first time we’ve seen this particular phenomenon, social distancing isn’t a new invention. Humans have always had good reasons to withdraw from society, often for the greater good. Among the champions of isolation and social distancing are astronauts and cosmonauts—including the late Al Worden—whose time in space has often been spent in extended periods of cramped loneliness, away from family and friends. They can serve as inspiration in these difficult times.

As a cultural anthropologist, my research focuses on human behavior, particularly types of behavior shared by groups, and it is clear that social distancing is unusual. Human beings are gregarious creatures and we do tend to be found in “corporate bodies,” ranging from small bands of 30 to 50 people all the way up to huge cities filled with millions. In band societies, everyone knows everyone else and there’s generally shared work, shared play, and lots of shared gossip. In larger societies, where we may be surrounded by virtual strangers, celebrities seem to fill in as the people everyone knows, giving us membership in a community where celebrities are “shared points of reference” (Hermes and Kooijmann 2016). I may not know you well, but we can probably talk to each other about Sigourney Weaver and Tom Hanks.

As the COVID-19 cases continue to rise globally, the National Medical Products Administration of China has approved the first-ever antiviral medicine called Favilavir. This medicine is said to possibly treat the now-declared pandemic illness.

Over the weekend, Taizhou’s city government announced that Favilavir, which was initially formulated by a Chinese-owned pharmaceutical firm, is the first medicine authorized to stop the widespread of this fatal illness. At present, this drug is being promoted with the label, Avigan.

According to the Ministry of Science and Technology of China, the Favilavir of Hisun Pharmaceutical is among the three drugs that have presented results for hindering COVID-19 (in initial trials) from spreading and further damaging the health of the people worldwide.

Engineers have created a tiny device that can rapidly detect harmful bacteria in blood, allowing health care professionals to pinpoint the cause of potentially deadly infections and fight them with drugs.

The Rutgers coauthored study, led by researchers at Rochester Institute of Technology, is published in the journal ACS Applied Materials & Interfaces.

“The rapid identification of drug-resistant bacteria allows to prescribe the right drugs, boosting the chances of survival,” said coauthor Ruo-Qian (Roger) Wang, an assistant professor in the Department of Civil and Environmental Engineering in the School of Engineering at Rutgers University-New Brunswick.

A Covid-19 test can deliver results in less than an hour has been approved under an FDA emergency authorization, marking the first test that clinicians can use at the bedside.

Testing shortages have been an ongoing challenge in the U.S. response to curb the pandemic. The White House has promised testing will ramp up as more private companies come on board.

Public health and clinical labs have run more than 195,000 tests to date, but that doesn’t include hospital laboratories running their own test, Brett Giroir, assistant secretary for health at the U.S. Department of Health and Human Services, said during a White House briefing Saturday.

At least five downtown Denver hotels have closed temporarily to stem the coronavirus spread, and the statewide industry is bracing for a hit that could lead to as many as 72,000 job losses in a sector that produces a $13.4 billion annual gross domestic product statewide.

While only a handful of mountain resorts had shut down by early this week, that number has ballooned in recent days as hotels across the metro region are reporting vacancy levels below 10% during a month many had predicted would be record-setting, Colorado Hotel and Lodging Association President/CEO Amie Mayhew said. Among those that have announced they will shutter until May 11 or 12 are the Grand Hyatt Denver, the Oxford Hotel, the Crawford Hotel and The Maven Hotel at Dairy Block.

All of those except for the Grand Hyatt are operated by Sage Hospitality Group of Denver, whose CEO, Walter Isenberg, issued a letter Thursday saying he’d made “the very difficult decision to temporarily suspend business operations at a portion of our hotels and restaurants in order to protect the health and safety of our guests, our associates and our communities.”

Dr. Ezekiel Emanuel, an American oncologist and bioethicist who is senior fellow at the Center for American Progress as well as Vice Provost for Global Initiatives at the University of Pennsylvania and chair of the Department of Medical Ethics and Health Policy, said on MSNBC on Friday, March 20, that Tesla and SpaceX CEO Elon Musk told him it would probably take 8–10 weeks to get ventilator production started at his factories (he’s working on this at Tesla and SpaceX).

I reached out to Musk for clarification on that topic and he replied that, “We have 250k N95 masks. Aiming to start distributing those to hospitals tomorrow night. Should have over 1000 ventilators by next week.” With medical supplies such as these being one of the biggest bottlenecks and challenges at the moment in the COVID-19 response in the United States (as well as elsewhere) — something that is already having a very real effect on medical professionals and patient care — the support will surely be received with much gratitude. That said, while there has been much attention put on the expected future need for ventilators, very few places reportedly have a shortage of them right now. In much greater need at the moment are simpler supplies like N95 masks, which must be why Tesla/SpaceX is providing 250,000 of them.

Dr. Emanuel also said in the segment of MSNBC’s “Morning Joe” he was on that we probably need 8–12 weeks (2–3 months) of social distancing in the US in order to deal with COVID-19 as a society. However, he also expects that the virus will come back and we’ll basically have a roller coaster of “social restrictions, easing up, social restrictions, easing up … to try to smooth out the demand on the health care system.”

“Infusions of antibody-laden blood have been used with reported success in prior outbreaks, including the SARS epidemic and the 1918 flu pandemic.”

John Hopkins University


With a vaccine for COVID-19 still a long way from being realized, Johns Hopkins immunologist Arturo Casadevall is working to revive a century-old blood-derived treatment for use in the United States in hopes of slowing the spread of the disease.

With the right pieces in place, the treatment could be set up at Johns Hopkins University in Baltimore within a matter of weeks, Casadevall says.

The technique uses antibodies from the blood plasma or serum of people who have recovered from COVID-19 infection to boost the immunity of newly infected patients and those at risk of contracting the disease. These antibodies contained in the blood’s serum have the ability to bind to and neutralize SARS-CoV-2, the virus that causes COVID-19. Casadevall—a Bloomberg Distinguished Professor of molecular microbiology and immunology and infectious diseases at the Johns Hopkins Bloomberg School of Public Health and School of Medicine—published a paper on the proposal today in The Journal of Clinical Investigation.

Bulky, buzzing and beeping hospital rooms demonstrate that monitoring a patient’s health status is an invasive and uncomfortable process, at best, and a dangerous process, at worst. Penn State researchers want to change that and make biosensors that could make health monitoring less bulky, more accurate—and much safer.

The key would be making sensors that are so stretchable and flexible that they can easily integrate with the human body’s complex, changing contours, said Larry Cheng, the Dorothy Quiggle Professor in Engineering and an affiliate of the Institute for Computational and Data Sciences. His lab is making progress on designing sensors that can do just that.

If biosensors that are both efficient and stretchable can be achieved at scale, the researchers suggest that engineers can pursue—and, in some cases, are already pursuing—a range of options for sensors that can be worn on the body, or even placed inside the body. The payoff would be smarter, more effective and more personalized medical treatment and improved health decision-making—without a lot of bulky, buzzing and beeping pieces of monitoring equipment.